



## Editorial

 Serum Biomarkers in Diffuse Interstitial Lung Diseases<sup>☆</sup>

## Biomarcadores séricos en las enfermedades pulmonares intersticiales difusas

 Jacobo Sellarés,<sup>a,c,d</sup> María Molina-Molina<sup>b,c,d,\*</sup>
<sup>a</sup> Servicio de Neumología, Instituto del Tórax, Hospital Clínico, IDIBAPS, Universidad de Barcelona, Barcelona, Spain

<sup>b</sup> Unidad Funcional de Intersticio Pulmonar (UFIP), Servicio de Neumología, Hospital Universitario de Bellvitge, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain

<sup>c</sup> Centro de Investigación Biomédica en Red-Enfermedades Respiratorias (CIBERES), Spain

<sup>d</sup> Barcelona Respiratory Network, Spain


Biomarkers or biological markers are defined as molecules, substances or clinical parameters that reflect the underlying biological processes involved in a disease.<sup>1</sup> Biomarkers can be classified in 4 ways: as indicative of risk or predisposition, or as diagnostic, prognostic, or therapeutic, depending on their function.<sup>1</sup> The clinical utility of biomarkers in diffuse interstitial lung diseases (ILD) has been evaluated primarily in idiopathic pulmonary fibrosis (IPF), although in recent years some promising biomarkers have also been identified in other ILDs.<sup>1–5</sup> The complexity of diagnosing and predicting the outcome of fibrosing ILDs has been challenging in the search for valid biomarkers, and, although many have been identified, very few have been easily obtainable or reproducible, or representative of the pulmonary process in the long term.<sup>1–7</sup> However, a few biomarkers with these characteristics are currently being validated with the collaboration of international networks, thanks to technological advances and the availability of registries and biobanks.<sup>5,8,9</sup> Pulmonary fibrosis biomarkers in serum that have been studied in most depth are divided into 3 categories: those associated with alveolar epithelial dysfunction, those associated with extracellular matrix remodeling and fibroproliferation, and those associated with the immune system regulation and host defense mechanisms.<sup>1,6,7</sup>

The most important genetic markers associated with epithelial-mesenchymal reparative changes are variants that encode proteins that synthesize or regulate the telomerase enzyme (TERT, TERC, DKC1, PARN, RTEL1, TINF1, OBFC1, NAF1), those that encode surfactant proteins (SFTPC, SFTPA2, ABCA3), and in the case of markers associated with ciliary changes and cellular defense alterations, the genetic mutation that encodes MUC5B.<sup>5,10–12</sup> A recent study that included thousands of patients with sporadic and familial IPF confirms that the common variant of the MUC5B gene, rs35705950, increases the risk of developing the disease, with an odds ratio (OR) of 5.45, 95% CI: 4.91–6.06 in the presence of a mutant allele, and an

OR 18.68, 95% CI: 13.34–26.17 in 2 mutant alleles.<sup>5</sup> Rare TERT and RTEL1 telomerase variants and telomere shortening are also associated with a greater risk of developing the disease.<sup>5,10</sup> Moreover, the presence of telomere shortening and telomerase mutations confer a worse prognosis in patients with IPF, especially in younger subjects, and warrant special considerations from a management and therapeutic perspective.<sup>10,11</sup> The presence of MUC5B polymorphism and telomere shortening has been associated with the pulmonary fibrosing component of other ILDs, such as rheumatoid arthritis or hypersensitivity pneumonitis, in which they have prognostic implications.<sup>12</sup> Gene expression has been shown to improve the multi-dimensional Gender, Age, and Physiology (GAP) predictive model that includes gender, age and forced vital capacity and lung diffusing capacity of CO.<sup>8</sup> As such, the study of genetic biomarkers involved in lung fibrogenesis could be useful in ILDs with limited survival associated with the fibrosing pulmonary component.

Protein biomarkers have also been evaluated for decades, but progress has only been achieved in recent years, thanks to research networks and group collaborations. Examples of these collaborative efforts are the PROFILE study and the EurIPFRegistry, which include hundreds of samples from IPF patients from different regions, while the PROFILE study also collected longitudinal serological determinations.<sup>4,9</sup> The most widely tested serum biomarkers are the following: (a) cytokines such as KL-6 (a marker of alveolar damage), which was particularly high in subjects with increased risk of exacerbations, and CCL-18, which was associated with poorer survival<sup>1</sup>; (b) metalloproteinases (MMP), mainly MMP-7 and MMP-1, associated with lung function decline and mortality<sup>2,3</sup>; (c) pulmonary surfactant products SPA, SPD, associated with increased alveolar damage<sup>2,3</sup>; (d) neoepitopes and collagen degradation substances as predictors of worse prognosis<sup>4</sup>; and (e) cell and tissue aging products such as the AGE/RAGE ratio or heat shock proteins (HSP) including HSP45, which show higher serum concentration in cases with more rapid progression.<sup>13</sup> Although these biomarkers have been validated in terms of prognostic capacity, most series include a limited number of cases and none has been a decisive factor in the differential diagnosis of the different fibrosing ILDs. Finally, some clinical trials, such as FLORA and INMARK, include serum biomarkers to monitor progression and pharmacological

<sup>☆</sup> Please cite this article as: Sellarés J, Molina-Molina M. Biomarcadores séricos en las enfermedades pulmonares intersticiales difusas. Arch Bronconeumol. 2020;56:349–350.

\* Corresponding author.

E-mail address: [mariamolinamolina@hotmail.com](mailto:mariamolinamolina@hotmail.com) (M. Molina-Molina).

effect. Of particular interest in the FLORA clinical trial was the effect of the drug GLPG1690 on lysophosphatidic acid levels in blood, which decreased when the compound was being administered and rose again after it was discontinued.<sup>14</sup>

In spite of the usefulness that some of these biomarkers have demonstrated in different studies, their use in daily clinical practice is limited and the international guidelines are slow to recommend their use.<sup>15</sup> As such, there is a gap between scientific advances and the information obtained through biomarkers and their use in clinical practice. Several reasons for this gap have been proposed, primarily: the general unavailability of the techniques specifically required for determining some biomarkers; the lack of efficiency studies that demonstrate cost-benefit compared to clinical parameters already in use; the absence of consensus on the most useful measurements; and the limited, though growing, scientific evidence from large, validated clinical trials. Just as international genetic studies have identified genetic variants that increase the risk of developing the disease, it is possible that in the near future international collaborative studies and clinical trials will identify a combination of serum biomarkers that, united in a single platform, can be evaluated correctly in different countries.

In conclusion, the progress of knowledge on serum biomarkers in interstitial diseases, and ILD in particular, may be one of the keys to optimizing the diagnosis, prognosis, and treatment of these patients. National and international collaboration among the various biobanks and registries is essential if we are to achieve these aims in minority diseases such as these.

## Funding

This document is the result of a Procon in IPD Biomarkers initiative conducted as part of the Seminar on Respiratory System Biomarkers of the Barcelona Respiratory Network (BRN).

## Conflict of interests

The research group led by the author receives or has received funding for the provision of scientific services and grants from Roche, Boehringer Ing, Chiesi, Esteve Teijin Healthcare, Linde, GSK, Astra-Zeneca, Intermune.

The research group led by Dr. James Sellarés has received funding for the provision of scientific services and grants from Roche Boehringer Ing, Chiesi, Menarini, GSK, Astra-Zeneca, Intermune, Novartis, Bial.

## References

1. Ley B, Brown KK, Collard HR. Molecular biomarkers in idiopathic pulmonary fibrosis. *Am J Physiol Cell Mol Physiol*. 2014;307:L681–91.
2. Rosas JO, Richards TJ, Konishi K, Zhang Y, Gibson K, Lokshin AE, et al. MMP1 and MMP7 as potential peripheral blood biomarkers in idiopathic pulmonary fibrosis. *PLoS Med*. 2008;5:0623–633.
3. Richards TJ, Kaminski N, Baribaud F, Flavin S, Brodmerkel C, Horowitz D, et al. Peripheral blood proteins predict mortality in idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med*. 2012;185:67–76.
4. Organ LA, Duggan AR, Oballa E, Taggart SC, Simpson JK, Kang'ombe AR, et al. Biomarkers of collagen synthesis predict progression in the PROFILE idiopathic pulmonary fibrosis cohort. *Respir Res*. 2019;20:148.
5. Moore C, Blumhagen RZ, Yang IV, Walts A, Powers J, Walker T, et al. Resequencing study confirms that host defense and cell senescence gene variants contribute to the risk of idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med*. 2019;200:199–208.
6. Vicens-Zygmunt V, Molina-Molina M. Biomarkers for diagnosis and prognosis. *Contemporary approaches to idiopathic pulmonary fibrosis*, Chapter 8. *Ed. Future Medicine*; 2015. p. 138–50, <http://dx.doi.org/10.2217/9781780845135>.
7. McDonough JE, Kaminski N, Thienpont B, Hogg JC, Vanaudenaerde BM, Wuyts WA. Gene correlation network analysis to identify regulatory factors in idiopathic pulmonary fibrosis. *Thorax*. 2019;74:132–40.
8. Herazo-Maya JD, Sun J, Molyneaux PL, Li Q, Villalba JA, Tzouveleki A, et al. Validation of a 52-gene risk profile for outcome prediction in patients with idiopathic pulmonary fibrosis: an international, multicentre, cohort study. *Lancet Respir Med*. 2017;5:857–68.
9. Guenther A, Krauss E, Tello S, Wagner J, Paul B, Kuhn S, et al. The European IPF registry (eurIPFreg): baseline characteristics and survival of patients with idiopathic pulmonary fibrosis. *Respir Res*. 2018;19:141.
10. Armanios M. Telomeres in the clinic not on TV. *Mayo Clin Proc*. 2018;93:815–7.
11. Molina-Molina M, Planas-Cerezales L, Perona R. Telomere shortening in idiopathic pulmonary fibrosis. *Arch Bronconeumol*. 2018;54:3–4.
12. Newton CA, Oldham JM, Ley B, Anand V, Adegunsoye A, Liu G, et al. Telomere length and genetic variant associations with interstitial lung disease progression and survival. *Eur Respir J*. 2019;53.
13. Machahua C, Montes-Worboys A, Planas-Cerezales L, Buendia-Flores R, Molina-Molina M, Vicens-Zygmunt V. Serum AGE/RAGEs as potential biomarker in idiopathic pulmonary fibrosis. *Respir Res*. 2018;19:215.
14. Maher TM, van der Aar EM, van de Steen O, Allamassey L, Desrivot J, Dupont S, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG1690, a novel autotaxin inhibitor, to treat idiopathic pulmonary fibrosis (FLORA): a phase 2a randomised placebo-controlled trial. *Lancet Respir Med*. 2018;6:627–35.
15. Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, et al. Diagnosis of idiopathic pulmonary fibrosis an official ATS/ERS/JRS/ALAT clinical practice guideline. *Am J Respir Med Crit Care*. 2018;198.